With years of independent innovation, our company currently possesses core technologies such as ZHPEG®、ZHBKKS™、ZHBody®、ZHBiAb®、ZHAIT™、ZHSLIT™、ZHPBM™and ZHCDX™. We have applied for more than 200 domestic and international patents, among which over 100 patents have been granted.
-
Long-acting Therapeutic Drug Core Technology — ZHPEG® and ZHBKKS™
By integrating modern chemical technology and molecular biology technology, we perform molecular design and modification of proteins and peptides. Using novel long-acting modification techniques, we have developed a new generation of biopharmaceutical drugs with long-acting, low immunogenicity, high stability, specific targeting, high bioavailability, and new dosage forms. These drugs are used to treat tumors, cardiovascular diseases, and endocrine system disorders.
-
Novel Targeted Antibody Core Technology — ZHBody® and ZHBiAb®
We design humanized antibodies and utilize our unique dual-specific antibody platform and mammalian expression platform to develop new dual-specific antibody drugs for immune therapy targeting hematologic malignancies and solid tumors. Compared to single-target antibodies, these drugs demonstrate better anti-tumor activity and safety. We are dedicated to the development of specific targeting human and humanized antibody drugs, aiming to provide new treatment options for clinical diseases.
-
Allergy Desensitization Drug Core Technology — ZHAIT™ and ZHSLIT™
Using modern biotechnology platforms and molecular immunology methods, we establish a research and translation platform for companion diagnostics. This platform is applied in early disease prevention and diagnosis, prediction of drug efficacy, identification of specific drug responders, and determination of drug dosage. By developing individualized treatment plans based on the concept of precision medicine, we aim to minimize adverse drug reactions, reduce medical costs, and maximize patient recovery.
-
Precision Diagnosis and Treatment Application Core Technology — ZHPBM™ and ZHCDX™
Using modern biotechnology platforms and molecular immunology methods, we establish a research and translation platform for companion diagnostics. This platform is applied in early disease prevention and diagnosis, prediction of drug efficacy, identification of specific drug responders, and determination of drug dosage. By developing individualized treatment plans based on the concept of precision medicine, we aim to minimize adverse drug reactions, reduce medical costs, and maximize patient recovery.